Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2023-03-10 Director's Dealing
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for 'notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It identifies a specific individual (Frederik Barfoed Beck), their position as a member of the Board of Directors, and details a sale of shares. This is a classic insider trading disclosure, which falls under the 'Director's Dealing' category.
2023-03-10 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard template for 'notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It explicitly identifies a member of the Board of Directors (Frederik Barfoed Beck) and details their exercise of warrants (transaction in shares). This aligns perfectly with the definition of a Director's Dealing report.
2023-03-10 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document is an announcement regarding transactions in company shares by persons discharging managerial responsibilities (PDMRs). While it contains links to specific transaction details, the primary purpose of this text is to report insider dealings as required by regulatory standards. According to the provided definitions, 'Director's Dealing' (DIRS) is the specific category for reports of personal share transactions by company directors and executives.
2023-03-10 Danish
Share Issue/Capital Change 2023
Share Issue/Capital Change Classification · 99% confidence The document is a company announcement (Company announcement – No. 3 / 2023) detailing a specific corporate action: the increase of share capital resulting from the exercise of employee warrants. This action directly impacts the company's capital structure by issuing new shares and receiving proceeds. This aligns precisely with the definition of 'Capital/Financing Update' (CAP), which covers fundraising, financing activities, or capital structure changes. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). It is a specific capital structure change announcement.
2023-03-09 English
Annual Report (ESEF) 2022
Annual Report (ESEF) Classification · 100% confidence FY 2022
2023-03-02 English
Annual Report 2022
Annual Report Classification · 100% confidence The document is clearly identified as an 'Annual Report 2022' for Zealand Pharma. It contains comprehensive sections including a management review, CEO letter, consolidated key figures, financial statements, and auditor's report. It is a full-year report covering company activity and financial performance, fitting the definition of a 10-K (Annual Report). FY 2022
2023-03-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.